| scholarly article | Q13442814 |
| P50 | author | Peter F Ambros | Q41883260 |
| Christian Dorfer | Q48238806 | ||
| Monika Chocholous | Q57421981 | ||
| P2093 | author name string | Irene Slavc | |
| Johannes Gojo | |||
| Karin Dieckmann | |||
| Christine Haberler | |||
| Asuka Araki | |||
| Harald Heinzl | |||
| Thomas Czech | |||
| Inge M Ambros | |||
| P2860 | cites work | Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma | Q24646111 |
| Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma | Q24652909 | ||
| Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma | Q24652958 | ||
| Targeting ECM Disrupts Cancer Progression | Q26779300 | ||
| Clinical impact and functional aspects of tenascin-C expression during glioma progression | Q28211100 | ||
| Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma | Q31084569 | ||
| C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma | Q33730977 | ||
| Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma | Q34085362 | ||
| Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma | Q34132926 | ||
| Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007 | Q34357043 | ||
| Radial glia cells are candidate stem cells of ependymoma | Q34459796 | ||
| Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma | Q34512893 | ||
| The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors | Q34726166 | ||
| Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. | Q34776024 | ||
| Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. | Q34963365 | ||
| Pediatric ependymoma: biological perspectives. | Q34987227 | ||
| Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts | Q35053098 | ||
| Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups | Q35746432 | ||
| Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups | Q35748208 | ||
| Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis | Q36344765 | ||
| Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups | Q36461766 | ||
| Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. | Q36560149 | ||
| Genetic abnormalities detected in ependymomas by comparative genomic hybridisation | Q36623735 | ||
| Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study | Q36737176 | ||
| The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma | Q37105296 | ||
| A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas | Q38094232 | ||
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
| Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system | Q39459076 | ||
| Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group | Q39652042 | ||
| Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy | Q39719582 | ||
| Evaluation of chromosome 1q gain in intracranial ependymomas. | Q40150706 | ||
| Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study | Q40521540 | ||
| EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study | Q42175070 | ||
| Study of chromosome 9q gain, Notch pathway regulators and Tenascin-C in ependymomas | Q44949318 | ||
| Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. | Q44958621 | ||
| The extracellular matrix glycoprotein Tenascin-C is expressed by oligodendrocyte precursor cells and required for the regulation of maturation rate, survival and responsiveness to platelet-derived growth factor | Q45153218 | ||
| Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. | Q45944762 | ||
| Molecular staging of intracranial ependymoma in children and adults | Q46526605 | ||
| Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study | Q48099096 | ||
| Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. | Q48364922 | ||
| Immunohistochemical markers for prognosis of ependymal neoplasms | Q48505500 | ||
| FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice – a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies ( | Q53627617 | ||
| Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signaling pathway. | Q55461138 | ||
| FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice - a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies ( | Q55463396 | ||
| Distribution of the extracellular matrix glycoproteins in ependymomas--an immunohistochemical study with follow-up analysis. | Q55472062 | ||
| Prognostic factors in intracranial ependymomas in children. | Q55475092 | ||
| Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. | Q55475232 | ||
| P433 | issue | 1 | |
| P921 | main subject | ependymoma | Q1346753 |
| pediatric ependymoma | Q7159224 | ||
| P304 | page(s) | 88 | |
| P577 | publication date | 2016-08-22 | |
| P1433 | published in | Acta Neuropathologica Communications | Q27724912 |
| P1476 | title | Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma | |
| P478 | volume | 4 |
| Q90085893 | An integrated molecular profile of endometrioid ovarian cancer |
| Q92377729 | Characterization of molecular signatures of supratentorial ependymomas |
| Q57171284 | Heterogeneity within the PF-EPN-B ependymoma subgroup |
| Q33803137 | Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification |
| Q89563166 | Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience |
| Q61805200 | Prognostic Role of Tenascin-C for Cancer Outcome: A Meta-Analysis |
| Q55176029 | Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor. |
| Q38858546 | Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain |
| Q64053923 | Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease |
Search more.